In nuclear medicine, the term theranostics describes the combination of therapy and
diagnostic imaging. In practice, this concept dates back more than 50 years; however …

Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues is an
emerging and convincing treatment modality for patients with unresectable, somatostatin …

Simple Summary This article discusses the use of peptide receptor radionuclide therapy
(PRRT) as a key treatment method for advanced, unresectable neuroendocrine tumors. It …

Theranostics and its principles: pre-treatment selection of patients who are most likely to
benefit from treatment by the use of a related, specific diagnostic test are integral to the …

The purpose of this guideline is to assist physicians caring for patients with neuroendocrine
tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) …

Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …

Nuclear medicine plays a pivotal role in the imaging and treatment of neuroendocrine
tumours (NETs). Somatostatin receptor scintigraphy (SRS) with [111 In-DTPA 0] octreotide …

The purpose of these guidelines is to assist physicians caring for patients with
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …

Evidence supporting the potential contribution of targeted radiotherapy to the management
of neuroendocrine tumours is now strong. Acting systemically, this is an effective option for …

Objectives Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin
analogues is a promising treatment for patients with inoperable, well to moderately …